Evaxion Biotech (EVAX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evaxion Biotech A/S, also known as NovVac A/S, aims to develop cutting-edge software for new immune therapies and vaccines. The company has a share capital of 55,760,546 DKK with shares that are non-negotiable and carry no special rights. Furthermore, the board is authorized to issue warrants and increase capital by up to 9,461,540 DKK until April 2029 to incentivize key company personnel, without pre-emptive rights for existing shareholders.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.